Skip to main
  1. Stocks
  2. Repligen
  3. Forecast
RGEN

Repligen (RGEN) Stock Forecast & Price Target

Repligen (RGEN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 50%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Repligen is supported by a resilient bioprocessing demand backdrop, with consumables growing about 20% and strong momentum in Chromatography (+50%), Proteins (+40%), and Process Analytics, while capital equipment orders rose in the mid-teens to their highest level in five years. Its FY26 organic growth guidance narrowed to 12-13% from 10.5-13.5%, adjusted operating income guidance increased to $135-139m from $128-134m, and China’s >40% growth with record orders suggests improving global demand beyond North America and EMEA. Even with Filtration softness and headwinds from new therapeutic modalities in 2025 and largely through 2026, the company’s broad franchise, improving operating leverage, and recovery profile support a positive long-term outlook.

Bears say

Repligen is vulnerable to multiple compression because it trades at a premium to the high-growth MedTools peer group, yet that premium depends on sales growth and profitability that may not meet expectations. Its downside is amplified by a sluggish recovery in equipment demand, since reshoring optimism has not translated into actual purchase orders, and by competitive threats to ATF products that represent nearly 20% of sales. In addition, exposure to risky cell and gene therapy and mRNA end markets, plus regulatory and larger-competitor pressure, could undermine fundamentals across its bioprocessing portfolio.

Repligen (RGEN) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 50% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.

Repligen (RGEN) Analyst Forecast & Price Prediction

Get the latest Repligen (RGEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Repligen (RGEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repligen (RGEN) Forecast

Analysts have given Repligen (RGEN) a Buy based on their latest research and market trends.

According to 12 analysts, Repligen (RGEN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $183.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $183.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repligen (RGEN)


Repligen (RGEN) Analyst Forecast & Price Prediction

Get the latest Repligen (RGEN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Repligen (RGEN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RGEN stock data and trends